List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 25 studies with search of: Open Studies | multiple myeloma | Doxil
Include studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Liposomal Doxorubicin/Melphalan/Bortezomib
2 Recruiting Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Doxil, melphalan, bortezomib
3 Not yet recruiting A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Doxorubicin Hydrochloride Liposome Injection- Test;   Drug: Doxorubicin Hydrochloride Liposome Injection- Reference
4 Recruiting Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed MM
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide, Pegylated Liposomal Doxorubicin, Dexamethasone
5 Recruiting Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Doxorubicin;   Drug: Bortezomib;   Drug: Filgrastim
6 Recruiting Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: melphalan;   Drug: pegylated liposomal doxorubicin hydrochloride
7 Recruiting Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: vorinostat
8 Recruiting Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With MM
Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide;   Drug: Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone
9 Recruiting Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib, Dexamethasone, Doxorubicin, Acetyl-L-Carnitine
10 Recruiting Bortezomib, Doxorubicin, and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Not Responded to Treatment
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride
11 Recruiting Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: pegylated liposomal doxorubicin hydrochloride
12 Recruiting Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Conditions: Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
Intervention: Drug: Oncaspar, Doxil, Decadron
13 Not yet recruiting Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: pegylated liposomal doxorubicin hydrochloride
14 Recruiting A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab)
15 Recruiting A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
Condition: Relapsed/Refractory Multiple Myeloma
Intervention: Drug: DVD-R
16 Recruiting PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Thalidomide;   Drug: Adriamycin;   Drug: Dexamethasone
17 Recruiting Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: allogeneic stem cell transplant versus second autologous transplantation;   Drug: RAD
18 Recruiting UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma
Condition: Multiple Myeloma
Interventions: Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
19 Not yet recruiting Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: lenalidomide;   Drug: melphalan;   Drug: thalidomide;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Other: laboratory biomarker analysis;   Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
20 Recruiting T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: peripheral blood stem cell transplantation

Previous Page Studies Shown (1-20) Next Page (21-25)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services